About
MeMed Diagnostics has developed and validated an immune-based protein signature, MeMed BV, which distinguishes between bacterial and viral infections, providing a powerful tool in the fight against resistant strains of bacteria. An ELISA format of MeMed BV called ImmunoXpert is cleared for use in the EU (CE-IVD), Switzerland, and Israel and is currently in pilot distribution in these areas. MeMed is also developing MeMed Key, a platform that paves the way for measuring multiple proteins and signatures, both conventional and innovative, with central lab precision at the point of care. MeMed Key will measure MeMed BV within minutes. In September 2021, the company was granted 510(k) clearance by the FDA for MeMed BV for adults and children.
Funding history · 5 rounds · $223.4M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is MeMed Diagnostics' primary product and its function?
- MeMed Diagnostics has developed MeMed BV, an immune-based protein signature that differentiates between bacterial and viral infections. An ELISA format of this product, ImmunoXpert, is cleared for use in the EU (CE-IVD), Switzerland, and Israel.
- When did MeMed Diagnostics receive FDA clearance for MeMed BV?
- In September 2021, MeMed Diagnostics was granted 510(k) clearance by the FDA for MeMed BV for use in adults and children.
- What is MeMed Key and what is its purpose?
- MeMed Key is a platform under development by MeMed Diagnostics designed to measure multiple proteins and signatures with central lab precision at the point of care, including MeMed BV, within minutes.
- What was the most recent funding round for MeMed Diagnostics and when did it occur?
- MeMed Diagnostics completed a Series E funding round in August 2021, with investors including La Maison Partners and OurCrowd. For full financing history, refer to startupim.
- Which healthcare provider was the first to include MeMed BV as part of routine care?
- In June 2022, Maccabi Healthcare Services announced it was the first HMO in the world to include the MeMed BV test as part of its routine care.
- When did MeMed Diagnostics partner with DiaSorin?
- In September 2020, DiaSorin and MeMed Diagnostics partnered to develop and commercialize novel host immune response-based diagnostics solutions.
- What was a significant regulatory approval for MeMed Diagnostics in March 2026?
- In March 2026, Health Canada approved MeMed BV on the MeMed Key platform, expanding MeMed Diagnostics' global footprint.
- When did MeMed Diagnostics receive CE Mark for its COVID-19 severity test?
- In July 2021, MeMed Diagnostics' COVID-19 severity test received its CE Mark, enabling it to predict severe outcomes.
- How many employees does MeMed Diagnostics currently have?
- MeMed Diagnostics currently has 105 employees.